[EN] PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS [FR] CARBAMATES DE PYRAZINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
[EN] PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS<br/>[FR] HÉTÉROARYLES À SUBSTITUTION PYRAZOLYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2017042100A1
公开(公告)日:2017-03-16
The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH, wherein R2 is selected from the group consisting of -C1-3-alkyl, -C1-3-haloalkyl, F, Br, CI, wherein Y is selected from -O- or -CH2-, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
申请人:JANSSEN PHARMACEUTICA NV
公开号:US20200392155A1
公开(公告)日:2020-12-17
Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
Pyrazolyl-substituted heteroaryls and their use as medicaments
申请人:Boehringer Ingelheim International GmbH
公开号:US10155751B2
公开(公告)日:2018-12-18
The invention relates to new substituted heteroaryls of formula 1
or of formula 1′
wherein A is either N or CH,
wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl,
wherein Y is selected from —O— or —CH2—,
and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof,
and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
本发明涉及式 1 的新取代杂芳基
或式 1′
其中 A 为 N 或 CH、
其中 R2 选自-C1-3-烷基、-C1-3-卤代烷基、F、Br、Cl 组成的组、
其中 Y 选自-O-或-CH2-、
其中 R3 的定义如权利要求 1 所述,及其药学上可接受的盐类、
以及将上述化合物用于治疗哮喘、慢性阻塞性肺病、过敏性鼻炎、过敏性皮炎、红斑狼疮、狼疮性肾炎和类风湿性关节炎等疾病。